Business Context and Reporting Period
This Form 8-K was filed by cbdMD, Inc. on May 17, 2022. The report details the issuance of unregistered equity securities pursuant to Item 3.02, specifically related to earnout rights from a 2018 merger agreement with Cure Based Development, LLC.
Key Financial Metrics
The filing does not provide comprehensive financial statements (e.g., total revenue, profit, cash flow, or debt levels) for the reporting period. The only specific financial metric disclosed is:
- Net Revenues (Q1 2022): $9,628,886 for the quarter ended March 31, 2022, which triggered the earnout provision.
Material Changes
The material event reported is the issuance of 458,877 shares of common stock to members of CBD Holding, LLC. This issuance was triggered by the company meeting specific aggregate net revenue criteria for the quarter ended March 31, 2022, within the third marking period of the amended Merger Agreement.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or discussion of general risks. The transaction was executed as an unregistered sale of equity securities to accredited investors, relying on the exemption provided by Section 4(a)(2) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance to assess dilution impact.
- Review the full terms of the Merger Agreement and Addendum No. 1 to understand remaining earnout thresholds and potential future share issuances.
- Confirm the identity of the recipients (affiliates of executive officers Martin A. Sumichrast and R. Scott Coffman) and their current holdings.
- Check subsequent filings for the company's full quarterly financial results to contextualize the $9.6 million revenue figure.